CA977279A - Tablet formulation containing a high percentage of allopurinol - Google Patents

Tablet formulation containing a high percentage of allopurinol

Info

Publication number
CA977279A
CA977279A CA200,536A CA200536A CA977279A CA 977279 A CA977279 A CA 977279A CA 200536 A CA200536 A CA 200536A CA 977279 A CA977279 A CA 977279A
Authority
CA
Canada
Prior art keywords
allopurinol
formulation containing
high percentage
tablet formulation
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA200,536A
Other languages
English (en)
Inventor
David Harden
Allan J. Torode
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of CA977279A publication Critical patent/CA977279A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA200,536A 1973-05-23 1974-05-22 Tablet formulation containing a high percentage of allopurinol Expired CA977279A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2462873A GB1460302A (en) 1973-05-23 1973-05-23 Tablet formulation

Publications (1)

Publication Number Publication Date
CA977279A true CA977279A (en) 1975-11-04

Family

ID=10214700

Family Applications (1)

Application Number Title Priority Date Filing Date
CA200,536A Expired CA977279A (en) 1973-05-23 1974-05-22 Tablet formulation containing a high percentage of allopurinol

Country Status (21)

Country Link
JP (1) JPS577128B2 (nl)
AT (1) AT351167B (nl)
AU (1) AU469472B2 (nl)
BE (1) BE815409A (nl)
CA (1) CA977279A (nl)
CY (1) CY941A (nl)
DE (1) DE2424950A1 (nl)
DK (1) DK144261C (nl)
FI (1) FI156674A (nl)
FR (1) FR2230341B1 (nl)
GB (1) GB1460302A (nl)
HK (1) HK1378A (nl)
HU (1) HU170656B (nl)
IE (1) IE39283B1 (nl)
IL (1) IL44877A (nl)
IT (1) IT8048966A0 (nl)
KE (1) KE2808A (nl)
MY (1) MY7800181A (nl)
NL (1) NL190436C (nl)
SE (1) SE402525C (nl)
ZA (1) ZA743318B (nl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1533243A (en) * 1975-02-13 1978-11-22 Wellcome Found Tablet formulation
US4143129A (en) 1975-10-11 1979-03-06 Lilly Industries Limited Cephalexin tablets
US4115563A (en) * 1977-03-14 1978-09-19 Sterling Drug Inc. Pharmaceutical steroid formulation
GB1601833A (en) * 1978-02-06 1981-11-04 Wellcome Found Antacid formulation
DE3839825A1 (de) * 1988-11-25 1990-06-13 Henning Berlin Gmbh Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze
WO1996002234A1 (es) * 1994-07-18 1996-02-01 Luis Cipriano Carvajal Martin Granulos compactos altamente autodisgregantes para uso en formas galenicas conteniendo principios activos insolubles o poco solubles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB975850A (en) * 1955-08-10 1964-11-18 Wellcome Found Xanthine oxidase inhibitors
US3624205A (en) * 1967-04-25 1971-11-30 Burroughs Wellcome Co Treatment of hyperuricemia in humans

Also Published As

Publication number Publication date
IT8048966A0 (it) 1980-06-13
JPS577128B2 (nl) 1982-02-09
NL7406873A (nl) 1974-11-26
FR2230341B1 (nl) 1977-04-15
KE2808A (en) 1978-02-17
NL190436C (nl) 1994-03-01
HU170656B (nl) 1977-07-28
JPS5040721A (nl) 1975-04-14
SE402525C (sv) 1982-11-22
DK144261C (da) 1991-02-04
DE2424950A1 (de) 1974-12-19
IL44877A (en) 1976-11-30
FI156674A (nl) 1974-11-24
HK1378A (en) 1978-01-13
CY941A (en) 1978-06-23
AU6925274A (en) 1975-11-27
FR2230341A1 (nl) 1974-12-20
SE402525B (sv) 1978-07-10
DK144261B (nl) 1982-02-01
IL44877A0 (en) 1974-07-31
IE39283B1 (en) 1978-09-13
MY7800181A (en) 1978-12-31
ZA743318B (en) 1975-05-28
AU469472B2 (en) 1976-02-12
AT351167B (de) 1979-07-10
NL190436B (nl) 1993-10-01
ATA426774A (de) 1978-12-15
GB1460302A (en) 1977-01-06
IE39283L (en) 1974-11-23
BE815409A (fr) 1974-11-22

Similar Documents

Publication Publication Date Title
CA1030871A (en) Pharmaceutical compositions
CA1026673A (en) Pharmaceutical compositions
AU497611B2 (en) Solid pharmaceutical formulation
CA1035792A (en) Preparation of 5-sec-alkyl-m-cresol
CA977279A (en) Tablet formulation containing a high percentage of allopurinol
MW174A1 (en) Pharmaceutical formulation
CA1024892A (en) Pharmaceutical compositions containing triazolo-isoquinoline derivatives
CA1001361A (en) Bleaching formulation
AU468465B2 (en) Tablet formulation
CA1028247A (en) Pharmaceutical compositions containing p-hydroxyacetanilide
CA1035503A (en) Ink formulation
CA1011010A (en) Fill-in compositions
CA975297A (en) Pharmaceutical composition containing a high percentage of allopurinol
CA1034498A (en) Diuretic formulations
ZA743282B (en) Novel hormonic formulation
CA1002469A (en) Marked capsule
CA1033741A (en) Derivatives of 4-hydroxy-5-azacoumarin
AU480639B2 (en) Pharmaceutical compositions containing triazolo-isoquinoline derivatives
AU480426B2 (en) Pharmaceutical tablets
CA996115A (fr) Piperazino-pyrimidines utilisables comme medicaments
AU495192B2 (en) Dehydroformylation of acetoxybutyraldehydes
AU495948B2 (en) Tablet formulation
AU494300B2 (en) Pharmaceutical compositions
AU478769B2 (en) Pharmaceutical compositions
AU485568B2 (en) Pharmaceutical compositions